## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.7% below STRENGTH zone (4.0-10.0%); PEG 35.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (44% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Reasons to Retain Baxter International Stock in Your Portfolio Now**
- Source: Finviz | 20251226T160752 | Somewhat-Bullish | Relevance: 100%
- Baxter International (BAX) is undergoing a transition post-Kidney Care divestiture, facing challenges such as the Novum Infusion Pump disruption and soft IV solutions demand, yet exhibiting strength in Advanced Surgery and Healthcare Systems. The company is actively focusing on deleveraging and operational discipline through initiatives like Baxter GPS. Despite near-term headwinds, BAX is working towards improving its financial flexibility and long-term shareholder returns, making it a current "Hold" according to Zacks.

**2. Programmable Infusion Pumps And Catheters Market 2025- 2032**
- Source: openPR.com | 20251226T120917 | Bullish | Relevance: 95%
- This report from Coherent Market Insights details the Programmable Infusion Pumps And Catheters Market from 2025 to 2032, highlighting key insights, segmentation, and growth opportunities. It covers strategic investment hotspots, regional trends, and profiles major industry players like ICU Medical, Inc., Smiths Group plc., and Baxter International Inc. The study provides a comprehensive analysis of market structure, performance, and future developments, aiding decision-makers in navigating the evolving landscape.

**3. Reasons to Retain Baxter International Stock in Your Portfolio Now**
- Source: TradingView â€” Track All Markets | 20251226T120728 | Neutral | Relevance: 95%
- Baxter International (BAX) is undergoing a transition post-divestiture of Kidney Care, facing near-term challenges but also long-term opportunities. The company exhibits resilience in its Advanced Surgery and Healthcare Systems businesses, alongside a strong focus on balance sheet deleveraging and operational discipline. Despite headwinds like the prolonged Novum Infusion Pump disruption and soft IV Solutions demand, these positive factors drive prospects and justify retaining the stock.

**4. Earnings Tell The Story For STERIS plc (NYSE:STE)**
- Source: Simply Wall Street | 20251226T193127 | Neutral | Relevance: 64%
- STERIS plc (NYSE:STE) currently has a high price-to-earnings (P/E) ratio of 36.4x, which is significantly above the market average. This elevated P/E is justified by the company's strong recent earnings growth of 17% and projected future growth of 14% per year, outpacing the broader market's 11% forecast. Investors seem to expect continued strong performance from STERIS, supporting its premium valuation.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.17M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.4x requires aggressive growth execution.
2. Elevated short interest (9.8%): bears positioning against stock.
3. Long-term trend broken: trading 25.0% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 35.42 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.42 |
| Forward P/E | 8.4 |
| Current P/E | 8.2 |
| YoY Growth | -2.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+1.0% over 5 days). Below STRENGTH zone by 2.3pp (needs >4.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Below SMA200 (0.75x), long-term trend not supportive. RSI neutral at 55. Volume at 44% of 20MA suggests lack of conviction. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.71% (CS: 74) | Neutral |
| RSI_14 | 55.1 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.027x | Above |
| vs SMA50 | 0.997x | Below |
| vs SMA200 | 0.750x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.38
- **Stop Loss:** $18.42 (5.0% risk)
- **Target:** $20.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1374
- **Position Value:** $26,628.12
- **Portfolio %:** 26.63%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*